New drug approvals in 2000.
Wynn
R L
RL
Department of Oral-Craniofacial Biological Sciences, Dental School, University of Maryland at Baltimore, USA.
D000081:Acetamides / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000779:Anesthetics, Local / Q000008:administration & dosage; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D017277:Drug Approval; D005233:Fatty Alcohols / Q000627:therapeutic use; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D000069349:Linezolid; D061466:Lopinavir; D018721:Muscarinic Agonists / Q000627:therapeutic use; D023303:Oxazolidinones / Q000627:therapeutic use; D004364:Pharmaceutical Preparations / Q000145:classification; D011744:Pyrimidinones / Q000627:therapeutic use; D011812:Quinuclidines / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use; D013876:Thiophenes; D014481:United States; D014486:United States Food and Drug Administration
D000081:Acetamides; D000779:Anesthetics, Local; D019380:Anti-HIV Agents; D000890:Anti-Infective Agents; D000998:Antiviral Agents; D005233:Fatty Alcohols; D017320:HIV Protease Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D018721:Muscarinic Agonists; D023303:Oxazolidinones; D004364:Pharmaceutical Preparations; D011744:Pyrimidinones; D011812:Quinuclidines; D013876:Thiophenes; D061466:Lopinavir; D000069036:Insulin Glargine; C529236:docosanol; D000069349:Linezolid; C059240:cevimeline; D019438:Ritonavir